Motley Fool Asset Management LLC Buys 172 Shares of McKesson Co. (NYSE:MCK)

Motley Fool Asset Management LLC lifted its stake in McKesson Co. (NYSE:MCK) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,951 shares of the company’s stock after buying an additional 172 shares during the quarter. Motley Fool Asset Management LLC’s holdings in McKesson were worth $1,829,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Stevens Capital Management LP grew its position in shares of McKesson by 107.5% during the fourth quarter. Stevens Capital Management LP now owns 2,723 shares of the company’s stock worth $1,261,000 after purchasing an additional 1,411 shares in the last quarter. Syon Capital LLC boosted its holdings in shares of McKesson by 40.7% in the 4th quarter. Syon Capital LLC now owns 2,538 shares of the company’s stock worth $1,175,000 after purchasing an additional 734 shares during the period. Bailard Inc. boosted its holdings in shares of McKesson by 71.2% in the 4th quarter. Bailard Inc. now owns 2,599 shares of the company’s stock worth $1,203,000 after purchasing an additional 1,081 shares during the period. BIP Wealth LLC boosted its holdings in shares of McKesson by 71.2% in the 4th quarter. BIP Wealth LLC now owns 3,039 shares of the company’s stock worth $1,407,000 after purchasing an additional 1,264 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of McKesson by 15.8% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,524 shares of the company’s stock worth $1,632,000 after acquiring an additional 481 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MCK shares. SVB Leerink started coverage on McKesson in a research note on Monday, February 26th. They set an “outperform” rating and a $600.00 price target for the company. Morgan Stanley lifted their target price on McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a research report on Monday, April 15th. Barclays assumed coverage on McKesson in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 price target for the company. UBS Group boosted their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of McKesson in a research note on Monday, February 26th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.50.

Insider Buying and Selling

In related news, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at $22,789,074.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other McKesson news, EVP Leann B. Smith sold 186 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now owns 43,445 shares in the company, valued at $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by company insiders.

McKesson Stock Performance

Shares of MCK stock traded up $3.43 during trading hours on Friday, reaching $543.37. The company had a trading volume of 654,667 shares, compared to its average volume of 686,507. The company has a market capitalization of $71.40 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 1.42 and a beta of 0.45. McKesson Co. has a 12-month low of $352.34 and a 12-month high of $544.81. The stock has a fifty day moving average of $528.15 and a 200-day moving average of $489.48.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping the consensus estimate of $7.05 by $0.69. The company had revenue of $80.90 billion during the quarter, compared to analyst estimates of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the business posted $6.90 earnings per share. On average, analysts forecast that McKesson Co. will post 27.59 EPS for the current year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, May 31st. This represents a $2.48 annualized dividend and a yield of 0.46%. McKesson’s payout ratio is 11.24%.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.